Investment analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Up 2.5 %
Shares of NASDAQ:PULM opened at $2.06 on Friday. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75. The firm has a fifty day moving average price of $2.09 and a 200 day moving average price of $1.97. The stock has a market capitalization of $7.52 million, a PE ratio of -0.85 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The company had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Use Stock Screeners to Find Stocks
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
